Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~PATIENT~1. Diseases~   Hematological malignancies confirmed histologically and not rapidly progressing:~  * AML in CR (defined as ≤ 5% marrow blasts and absence of blasts in the peripheral blood);~  * MDS with ≤ 5% marrow blasts and absence of blasts in the peripheral blood;~  * CML in CP;~  * MPS not in blast crisis and not with extensive marrow fibrosis,~  * ALL in CR;~  * Multiple myeloma not rapidly progressing;~  * CLL;~  * Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);~  * Hodgkin's disease with chemosensitive disease.~2. Clinical situations~   * Theoretical indication for a standard allo-transplant, but not feasible because:~     * Age \> 50 yrs;~    * Unacceptable end organ performance;~    * Patient's refusal.~  * Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.~3. Other inclusion criteria~   * Male or female; fertile patients must use a reliable contraception method;~  * Age \< 75 yrs;~  * Informed consent given by patient or his/her guardian if of minor age.~DONOR~* Related to the recipient (sibling, parent or child) or unrelated;~* Male or female;~* Any age;~* 10 of 10 (HLA-A, -B, -C, -DRB1, and -DQB1) HLA allele matched;~* Weight \> 15 Kg (because of leukapheresis);~* Fulfills criteria for allogeneic PBSC donation according to standard procedures;~* Informed consent given by donor or his/her guardian if of minor age, as per donor center standard procedures.~Exclusion Criteria:~PATIENT~* Any condition not fulfilling inclusion criteria;~* HIV positive;~* Non-hematological malignancy(ies) (except non-melanoma skin cancer) \< 3 years before nonmyeloablative HCT.~* Life expectancy severely limited by disease other than malignancy;~* Administration of cytotoxic agent(s) for cytoreduction within three weeks prior to initiating the nonmyeloablative transplant conditioning (Exceptions are hydroxyurea and imatinib mesylate);~* CNS involvement with disease refractory to intrathecal chemotherapy.~* Terminal organ failure, except for renal failure (dialysis acceptable)~* Uncontrolled infection;~* Karnofsky Performance Score \<70%;~* Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment;~* Patient is a female who is pregnant or breastfeeding;~* Previous radiation therapy precluding the use of 2 Gy TBI or 8 Gy TLI;~DONOR~* Any condition not fulfilling inclusion criteria;~* Unable to undergo leukapheresis because of poor vein access or other reasons.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- TBI + fludarabine (Type: ACTIVE_COMPARATOR): Conditioning regimen consisting of fludarabine 30 mg/m2 on days -4, -3 and -2 (total dose 90 mg/m2), followed by a singe dose of 2 Gy TBI administered on day 0, at a low dose-rate (≈ 7 cGy/min), before infusion of cells.
- TLI + ATG (Type: ACTIVE_COMPARATOR): Conditioning consisting of 8 Gy TLI and ATG. TLI will be administered by linear accelerator at a dose of 80 cGy daily, starting 11 days before transplantation, until a total of 10 doses (800 cGy) has been delivered. The irradiation will consist of a supradiaphragmatic mantle field, a subdiaphragmatic field including an inverted Y and splenic ports, encompassing all major lymphoid organs, including the thymus, spleen, and lymph nodes, as used in the treatment of Hodgkin's disease (Kaplan HS, Cancer Research 26:1268-1276, 1966). The Waldeyer ring is not included. ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.

Based on this trial design, predict the completion outcome and termination type (if applicable).